---
title: "BioNTech (NASDAQ:BNTX) Sees Large Volume Increase  - Here's Why"
description: "BioNTech (NASDAQ:BNTX) experienced a significant increase in trading volume, with approximately 1.33 million shares traded, a 43% rise from the previous session. The stock price rose to $116.20 from $"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242978013.md"
published_at: "2025-06-03T16:54:27.000Z"
---

# BioNTech (NASDAQ:BNTX) Sees Large Volume Increase  - Here's Why

> BioNTech (NASDAQ:BNTX) experienced a significant increase in trading volume, with approximately 1.33 million shares traded, a 43% rise from the previous session. The stock price rose to $116.20 from $113.10. Analysts have mixed ratings, with one sell, four holds, and thirteen buy ratings. The consensus target price is $139.14. BioNTech reported a quarterly EPS of $1.08, exceeding estimates, but revenue fell 19.5% year-over-year. Institutional investors have increased their stakes in the company, which focuses on developing immunotherapies for cancer and infectious diseases.

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 1,330,327 shares changed hands during trading, an increase of 43% from the previous session's volume of 930,600 shares.The stock last traded at $116.20 and had previously closed at $113.10.

## Wall Street Analysts Forecast Growth

-   4 Reasons Pfizer Could Be a Value Play You Can't Miss

BNTX has been the topic of several recent analyst reports. Wall Street Zen cut BioNTech from a "hold" rating to a "sell" rating in a research note on Friday. Morgan Stanley dropped their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Canaccord Genuity Group restated a "buy" rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Citigroup reaffirmed a "buy" rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. decreased their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $139.14.

**Check Out Our Latest Stock Report on BioNTech**

## BioNTech Stock Performance

-   Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?

The business has a fifty day simple moving average of $97.78 and a 200-day simple moving average of $108.21. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.38 billion, a P/E ratio of -56.22 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The company's quarterly revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.

## Institutional Inflows and Outflows

-   Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in BioNTech in the 4th quarter worth approximately $1,118,000. Van ECK Associates Corp lifted its holdings in BioNTech by 25.1% in the 4th quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after purchasing an additional 23,733 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in BioNTech by 39.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock worth $21,349,000 after purchasing an additional 53,319 shares in the last quarter. Finally, abrdn plc lifted its holdings in BioNTech by 70.7% in the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after purchasing an additional 159,676 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

## BioNTech Company Profile

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

## Featured Articles

-   Five stocks we like better than BioNTech
-   About the Markup Calculator
-   Broadcom Earnings Preview: AVGO Stock Near Record Highs
-   What is a Special Dividend?
-   3 Reasons Amazon Could Be the Best Tech Performer in June
-   What to Know About Investing in Penny Stocks
-   Palantir Soars on Government Deals as Valuation Debate Lingers

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in BioNTech Right Now?

Before you consider BioNTech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.

While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [BNTX.US - BioNTech SE](https://longbridge.com/en/quote/BNTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 新增用户数创纪录、利润增长 200%！“线上音乐巨头” Spotify“成功涨价” | Spotify 第四季度财报显示，得益于涨价策略的成功执行，公司净利润同比激增两倍至 11.7 亿欧元，每股收益远超市场预期。同时，月活跃用户数创纪录地增加了 3800 万，达到 7.51 亿，证明了用户对价格调整的接受度。受此提振，公司股 | [Link](https://longbridge.com/en/news/275526865.md) |
| 欧洲议会表决通过：支持推出兼具线上与线下功能的数字欧元 | 欧洲议会投票支持同时推出线上与线下形式的数字欧元，推翻了此前仅限线下的提议，与欧洲央行立场一致。此举旨在降低对 Visa 等支付公司的依赖，维护欧盟货币主权，并计划于 2027 年启动试点、2029 年正式推出。议会强调，若支付系统数字化由 | [Link](https://longbridge.com/en/news/275483373.md) |
| 欧央行经济学家：关税冲击拖累通胀，降息有望抵消负面影响 | 欧洲央行经济学家最新研究显示，美国关税政策正在抑制欧元区经济增长与通胀水平。研究指出，关税主要通过压低需求对价格产生下行压力，而受影响最深的行业（如机械、汽车和化工）对利率变化高度敏感。欧央行可通过降低利率，部分缓解关税对这些关键行业的冲击 | [Link](https://longbridge.com/en/news/275445096.md) |
| 随着南卡罗来纳州麻疹病例的增加，FDA 的 Makary 支持接种麻疹疫苗 | 美国食品药品监督管理局局长马丁·马卡里呼吁美国人接种麻疹疫苗，因为南卡罗来纳州正经历严重疫情，已报告 950 例病例，主要发生在未接种疫苗的人群中。马卡里强调了麻腮风疫苗的重要性，建议儿童在 12 个月大时接种，4 至 6 岁时接种第二剂。 | [Link](https://longbridge.com/en/news/275950694.md) |
| 由于 ‘医疗自由’ 的推动，美国正经历 30 年来最严重的麻疹爆发，医生们因此承受着巨大的压力 | 美国 30 多年来最大的麻疹疫情正在南卡罗来纳州爆发，报告病例超过 930 例。医疗人员正在进行户外分诊，以防止病毒在诊所内传播。由于错误信息和对 COVID-19 措施的反对，疫苗反对情绪导致免疫接种率下降，只有 89% 的学生按时接种疫 | [Link](https://longbridge.com/en/news/275888695.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
